{
  "id": "international_prognostic_index_chronic_lymphocytic_leukemia.v0",
  "gdl_version": "2.0",
  "concept": "gt0001",
  "language": {
    "original_language": "ISO_639-1::en"
  },
  "description": {
    "original_author": {
      "date": "2020-08-19",
      "name": "Therese Lindberg",
      "organisation": "Cambio CDS",
      "email": "therese.lindberg@cambio.se"
    },
    "lifecycle_state": "Initial",
    "details": {
      "en": {
        "id": "en",
        "purpose": "To stratify patients with chronic lymphocytic leukemia into four risk categories: low risk, intermediate risk, high risk and very high risk group.",
        "keywords": [
          "international prognostic index",
          "chronic lymphocytic leukemia",
          "CLL-IPI",
          "clinical stage",
          "age",
          "serum β2 microglobulin",
          "IGHV",
          "TP53",
          "status",
          "risk",
          "surivival"
        ],
        "use": "CLL-IPI Score is calculated from 5 parameters: Age, Clinical stage, Serum β2 microglobulin, IGHV mutational status and TP53 status.\n\nInterpretation:\nCLL-IPI Score         Risk                          5-year survival\n0-1                          Low risk                      93.2%\n2-3                          Intermediate risk        79.3%\n4-6                          High risk                     63.3%\n7-10                        Very high risk             23.3%",
        "copyright": "@CambioCDS"
      }
    },
    "other_details": {
      "references": "1. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-90."
    }
  },
  "definition": {
    "data_bindings": {
      "gt0002": {
        "id": "gt0002",
        "model_id": "openEHR-EHR-OBSERVATION.basic_demographic.v1",
        "template_id": "openEHR-EHR-OBSERVATION.basic_demographic.v1",
        "type": "INPUT",
        "elements": {
          "gt0003": {
            "id": "gt0003",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0013]"
          }
        }
      },
      "gt0004": {
        "id": "gt0004",
        "model_id": "openEHR-EHR-OBSERVATION.lab_test_serum_b2_microglobulin.v0",
        "template_id": "openEHR-EHR-OBSERVATION.lab_test_serum_b2_microglobulin.v0",
        "type": "INPUT",
        "elements": {
          "gt0005": {
            "id": "gt0005",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0004]"
          }
        }
      },
      "gt0006": {
        "id": "gt0006",
        "model_id": "openEHR-EHR-EVALUATION.international_prognostic_index_chronic_lymphocytic_leukemia.v0",
        "template_id": "openEHR-EHR-EVALUATION.international_prognostic_index_chronic_lymphocytic_leukemia.v0",
        "type": "INPUT",
        "elements": {
          "gt0007": {
            "id": "gt0007",
            "path": "/data[at0001]/items[at0003]"
          },
          "gt0008": {
            "id": "gt0008",
            "path": "/data[at0001]/items[at0005]"
          },
          "gt0009": {
            "id": "gt0009",
            "path": "/data[at0001]/items[at0006]"
          }
        }
      },
      "gt0010": {
        "id": "gt0010",
        "model_id": "openEHR-EHR-EVALUATION.international_prognostic_index_chronic_lymphocytic_leukemia.v0",
        "template_id": "openEHR-EHR-EVALUATION.international_prognostic_index_chronic_lymphocytic_leukemia.v0",
        "type": "OUTPUT",
        "elements": {
          "gt0011": {
            "id": "gt0011",
            "path": "/data[at0001]/items[at0002]"
          },
          "gt0012": {
            "id": "gt0012",
            "path": "/data[at0001]/items[at0004]"
          },
          "gt0013": {
            "id": "gt0013",
            "path": "/data[at0001]/items[at0017]"
          },
          "gt0014": {
            "id": "gt0014",
            "path": "/data[at0001]/items[at0018]"
          },
          "gt0015": {
            "id": "gt0015",
            "path": "/data[at0001]/items[at0023]"
          }
        }
      }
    },
    "rules": {
      "gt0016": {
        "id": "gt0016",
        "priority": 9,
        "when": [
          "$gt0003|Age|<=65,a"
        ],
        "then": [
          "$gt0011|Age|=0|local::at0007|≤65 years|"
        ]
      },
      "gt0017": {
        "id": "gt0017",
        "priority": 8,
        "when": [
          "$gt0003|Age|>65,a"
        ],
        "then": [
          "$gt0011|Age|=1|local::at0008|>65 years|"
        ]
      },
      "gt0018": {
        "id": "gt0018",
        "priority": 7,
        "when": [
          "($gt0005|Serum β2 microglobulin|<=3.5,mg/l)||($gt0005|Serum β2 microglobulin|<=3.5,ug/ml)"
        ],
        "then": [
          "$gt0012|Serum β2 microglobulin, mg/L (or µg/mL)|=0|local::at0011|≤3.5|"
        ]
      },
      "gt0019": {
        "id": "gt0019",
        "priority": 6,
        "when": [
          "($gt0005|Serum β2 microglobulin|>3.5,mg/l)||($gt0005|Serum β2 microglobulin|>3.5,ug/ml)"
        ],
        "then": [
          "$gt0012|Serum β2 microglobulin, mg/L (or µg/mL)|=2|local::at0012|>3.5|"
        ]
      },
      "gt0020": {
        "id": "gt0020",
        "priority": 5,
        "when": [
          "$gt0003|Age|!=null",
          "$gt0005|Serum β2 microglobulin|!=null",
          "$gt0007|Clinical stage|!=null",
          "$gt0008|IGHV mutational status|!=null",
          "$gt0009|TP53 status|!=null"
        ],
        "then": [
          "$gt0013|CLL-IPI Score|.magnitude=$gt0007.value+$gt0008.value+$gt0009.value+$gt0011.value+$gt0012.value"
        ]
      },
      "gt0021": {
        "id": "gt0021",
        "priority": 4,
        "when": [
          "$gt0013|CLL-IPI Score|>6",
          "$gt0013|CLL-IPI Score|<=10"
        ],
        "then": [
          "$gt0014|Risk|=local::at0022|Very high risk|",
          "$gt0015|5-year survival|=local::at0027|23.3%|"
        ]
      },
      "gt0022": {
        "id": "gt0022",
        "priority": 3,
        "when": [
          "$gt0013|CLL-IPI Score|>3",
          "$gt0013|CLL-IPI Score|<=6"
        ],
        "then": [
          "$gt0014|Risk|=local::at0021|High risk|",
          "$gt0015|5-year survival|=local::at0026|63.3%|"
        ]
      },
      "gt0023": {
        "id": "gt0023",
        "priority": 2,
        "when": [
          "$gt0013|CLL-IPI Score|>1",
          "$gt0013|CLL-IPI Score|<=3"
        ],
        "then": [
          "$gt0014|Risk|=local::at0020|Intermediate risk|",
          "$gt0015|5-year survival|=local::at0025|79.3%|"
        ]
      },
      "gt0024": {
        "id": "gt0024",
        "priority": 1,
        "when": [
          "$gt0013|CLL-IPI Score|>=0",
          "$gt0013|CLL-IPI Score|<=1"
        ],
        "then": [
          "$gt0014|Risk|=local::at0019|Low risk|",
          "$gt0015|5-year survival|=local::at0024|93.2%|"
        ]
      }
    }
  },
  "ontology": {
    "term_definitions": {
      "en": {
        "id": "en",
        "terms": {
          "gt0001": {
            "id": "gt0001",
            "text": "International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI)",
            "description": "International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) stratifies patients with chronic lymphocytic leukemia into four risk categories."
          },
          "gt0003": {
            "id": "gt0003",
            "text": "Age",
            "description": "Age in years, and for babies: months, weeks or days"
          },
          "gt0005": {
            "id": "gt0005",
            "text": "Serum β2 microglobulin",
            "description": "*"
          },
          "gt0007": {
            "id": "gt0007",
            "text": "Clinical stage",
            "description": "*"
          },
          "gt0008": {
            "id": "gt0008",
            "text": "IGHV mutational status",
            "description": "*"
          },
          "gt0009": {
            "id": "gt0009",
            "text": "TP53 status",
            "description": "*"
          },
          "gt0011": {
            "id": "gt0011",
            "text": "Age",
            "description": "*"
          },
          "gt0012": {
            "id": "gt0012",
            "text": "Serum β2 microglobulin, mg/L (or µg/mL)",
            "description": "*"
          },
          "gt0013": {
            "id": "gt0013",
            "text": "CLL-IPI Score",
            "description": "*"
          },
          "gt0014": {
            "id": "gt0014",
            "text": "Risk",
            "description": "*"
          },
          "gt0015": {
            "id": "gt0015",
            "text": "5-year survival",
            "description": "*"
          },
          "gt0016": {
            "id": "gt0016",
            "text": "Age ≤65 years"
          },
          "gt0017": {
            "id": "gt0017",
            "text": "Age > 65 years"
          },
          "gt0018": {
            "id": "gt0018",
            "text": "Serum β2 microglobulin ≤ 3.5"
          },
          "gt0019": {
            "id": "gt0019",
            "text": "Serum β2 microglobulin > 3.5"
          },
          "gt0020": {
            "id": "gt0020",
            "text": "Calculate CLL-IPI Score"
          },
          "gt0021": {
            "id": "gt0021",
            "text": "Very high Risk"
          },
          "gt0022": {
            "id": "gt0022",
            "text": "High Risk"
          },
          "gt0023": {
            "id": "gt0023",
            "text": "Intermediate Risk"
          },
          "gt0024": {
            "id": "gt0024",
            "text": "Low Risk"
          }
        }
      }
    }
  }
}